J.E. Mellerio proposed, in a short review devoted to potential therapeutic approaches to EBS, the development of more specific targeted therapies for EBS, with anti-IL-17 agents, which would be capable of targeting the Th17 response [160]. This evidence concerns the gene IL17A and epidermolysis bullosa simplex.